- 1 Comparison of the reactogenicity and immunogenicity of a reduced and standard booster
- 2 dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated
- 3 vaccine.

- 5 Sitthichai Kanokudom a,b, Suvichada Assawakosri a,b, Nungruthai Suntronwong a, Jira
- 6 Chansaenroj ^a, Chompoonut Auphimai ^a, Pornjarim Nilyanimit ^a, Preeyaporn Vichaiwattana ^a,
- 7 Thanunrat Thongmee^a, Ritthideach Yorsaeng ^a, Thaneeya Duangchinda ^c, Warangkana Chantima
- 8 d,e, Pattarakul Pakchotanon c, Donchida Srimuan a, Thaksaporn Thatsanatorn a, Sirapa Klinfueng
- 9 a, Juthathip Mongkolsapaya f,g, Natthinee Sudhinaraset a, Nasamon Wanlapakorn a, Sittisak
- 10 Honsawek b,* and Yong Poovorawan a,h,*
- a Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
- Bangkok 10330, Thailand.
- b Department of Biochemistry, Osteoarthritis and Musculoskeleton Research Unit, Faculty of
- Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red
- 15 Cross Society, Bangkok 10330, Thailand.
- 16 c Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic
- 17 Engineering and Biotechnology, National Science and Development Agency, NSTDA,
- Pathum Thani 12120, Thailand.
- d Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine, Siriraj Hospital,
- 20 Mahidol University, Bangkok 10700, Thailand.
- e Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of
- Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
- 23 f Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of
- Oxford, Oxford, OX3 7BN, UK.
- 25 g Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford,
- 26 Oxford, UK.

28

- 27 h The Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand.
- *Correspondence: Sittisak.h@chula.ac.th (S.H.); yong.p@chula.ac.th (Y.P.); Tel.: +662-256-
- 30 4452 (S.H.); +662-256-4929 (Y.P.)

Highlights:

32

39

40

41

- The 15 μg- and 30 μg-BNT162b2, and 50 μg- and 100 μg-mRNA-1273 booster doses
 were compared
- Booster vaccination with the mRNA vaccine elicits high Ig and IgG anti-RBD in
 CoronaVac-vaccinated adults
- No differences were observed in antibody responses after the reduced or standard booster
 dose of the mRNA vaccine in CoronaVac-vaccinated adults
 - Neutralizing antibodies against the delta and omicron variants were significantly higher after the booster dose
 - Neutralizing antibody titers were lower against the omicron variant than the delta variant in all vaccinated adults

Abstract: The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare 43 problem worldwide since December 2019. The third dose of heterologous vaccine was recently 44 approved by World Health Organization. The present study compared the reactogenicity and 45 immunogenicity of the reduced and standard third booster dose of the BNT162b2 and mRNA-46 1273 vaccine in adults who previously received the two-dose CoronaVac vaccine. Results 47 showed that headache, joint pain, and diarrhea were more frequent in the 15 µg- than the 30 µg-48 BNT162b2 groups, whereas joint pain and chilling were more frequent in the 100 µg- than the 50 49 50 μg-mRNA-1273 groups. No significant differences in immunogenicity were detected. These findings demonstrate that the reduced dose of the mRNA vaccines elicited antibody responses 51 against the SARS-CoV-2 delta and omicron variants that were comparable to the standard dose. 52 The reduced dose could be used to increase vaccine coverage in situations of limited global 53 54 vaccine supply. 55 **Keywords**: COVID-19; delta; omicron; booster; third dose; inactivated vaccine; mRNA vaccine;

56

standard dose; reduced dose; clinical trial.

1. Background

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

A shortage of the coronavirus disease 2019 (COVID-19) vaccine has been reported in several countries [2]. Vaccine importing countries, including Thailand, are affected by vaccine shortage, resulting in delays in the vaccination schedule. A dose reduction strategy can help countries to save costs on the imported vaccine and distribute vaccine more quickly during the COVID-19 outbreak. Several countries achieved high two-dose COVID-19 vaccination coverage but have been unable to control the spread of SARS-CoV-2. The delta and omicron variants have recently spread worldwide [3], and are causing breakthrough infection in vaccinated individuals [4, 5]. A preliminary study showed that vaccination of inactivated vaccine-vaccinated adults with a 15 µg-BNT162b2 mRNA dose elicited high immune responses against the SARS-CoV-2 delta variant [6, 7]. Our previous study demonstrated that individuals who received inactivated vaccines as their primary series achieved a high immune response against delta and omicron variants following receipt of a booster vaccination with the standard dose of BNT162b2 or mRNA-1273 [1]. However, it remains unclear whether a half-dose booster of an mRNA vaccine, especially a 50 µg-mRNA-1273 vaccination following the inactivated vaccine primary series, could induce adequate neutralization of the SARS-CoV-2 delta and omicron variants. Our study compared the reactogenicity and immunogenicity of reduced and standard doses of the BNT162b2 and mRNA-1273 vaccines in CoronaVac (CV)-vaccinated individuals.

2. Materials and methods

2.1. Study Design

This prospective cohort study enrolled healthy Thai adults ≥18 years of age without previous COVID-19 infection by medical interview at the time of enrollment. Adults who were immunized with the two-dose CV 6 months (± 1 month) after the second dose and consented to receive the 15 μg- BNT162b2 (n=59) or 50 μg-mRNA-1273 (n=51) reduced dose of the mRNA COVID-19 vaccine booster between November to December 2021 were included in the study. The comparison group included individuals who received the standard dose of either BNT162b2 (Pfizer-BioNTech Inc., NY) (n=54) or mRNA-1273 (Moderna Inc., Cambridge, MA) (n=58) for a previous study conducted between September and December 2021 [1]. The study protocol was approved by the Institutional Review Board (IRB) in the Faculty of Medicine at Chulalongkorn University (IRB690/64). This trial was included on the Thai Clinical Trials Registry (TCTR

- 88 20210910002). Written informed consent was obtained from participants prior to enrollment.
- 89 The study was conducted according to the Declaration of Helsinki and the principle of Good
- 90 Clinical Practice Guidelines (ICH-GCP). Blood samples were collected before vaccination (V1,
- day 0, baseline) and after receipt of the booster dose (V2, the second visit day 14 ± 7 and V3, the
- 92 third visit, day 28 ± 7) (Supplementary Figure S1).
 - 2.2. Vaccines

103

112

- The BNT162b (Pfizer-BioNTech Inc., New York, NY) contains 15 μg (reduced) or 30 μg
- 95 (standard) of mRNA encoding SARS-CoV2 spike (S) protein [8]. The mRNA-1273 (Moderna
- 96 Inc., Cambridge, MA) contains 50 μg (reduced) or 100 μg (standard) of mRNA encoding SARS-
- 97 CoV2 S protein [9].
- 98 2.3. Reactogenicity Assessment
- The subjects were continuously monitored for local, systemic, and any adverse events
- 100 (AEs) following immunization (AEFIs) occurring within 7 days using an online or paper-based
- self-assessment questionnaire. The data collection protocol was given to participants by trained
- investigators during the initial visit.

2.4. Laboratory Measurements

- Serum samples were collected for analysis of total immunoglobulin (Ig) specific to the
- receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, the IgG anti-RBD, the IgG
- anti nucleoprotein (anti-N), the neutralization assay against delta (B.1.617.2) and omicron
- 107 (B.1.1.529/BA.1) variants using surrogate virus neutralization test (sVNT), and the 50% focus
- reduction neutralization test (FRNT₅₀) as previously described [1, 10]. The seropositivity rate of
- sVNT showed > 30% inhibition, and the seropositivity rate of FRNT₅₀ was > 20-serum dilution.
- The assay used to measure the interferon-gamma (IFN-γ) SARS-CoV-2 releasing T cell response
- was performed on a heparinized whole blood sample as previously described [10].
 - 2.5. Statistical Analysis
- The sample size was calculated using G*power software version 3.1.9.6 (based on
- conventional effect size = 0.25, given significance level (α) = 0.05, power (1- β) = 0.8, numerator
- degree of freedom = 3, and number of groups = 4). The graphical representation and statistical

analyses were carried out using GraphPad Prism version 9.3.1. Categorical analyses of age and sex were performed using the Chi-square test. Adverse events were analyzed using the risk difference with a 95% confidence interval (CI). IgG-specific RBDs and FRNT₅₀ were designated as geometric mean titers (GMT) with a 95% CI. Other parameters were presented as medians with interquartile ranges. The differences in antibody titers, S/C, and percentage inhibition and IU/mL minus nil between groups were calculated using the Kruskal–Wallis or Wilcoxon signed-rank test (non-parametric) with multiple comparison adjustments. A *p*-value of <0.05 was considered statistically significant.

3. Results

3.1. Demographic data

A total of 222 healthy participants were analyzed, including 110 participants enrolled to receive the reduced vaccine dose and 112 participants who received the standard vaccine dose and were enrolled in a prior study in September 2021 [1]. The baseline demographic characteristics of participants in all four groups who received reduced or standard doses of the BNT162b2 or mRNA-1273 vaccines were generally comparable (Table 1). The mean age of participants who received the 15 μ g-BNT162b2, 30 μ g-BNT162b2, 50 μ g-mRNA-1273, or 100 μ g-mRNA-1273 vaccines were 39.1 \pm 10.0, 41.6 \pm 10.1, 38.7 \pm 11.1, and 37.0 \pm 10.5 years, respectively. No significant differences in age and sex were observed between the groups. Underlying diseases of the enrolled participants included allergy, diabetes mellitus, dyslipidemia, hypertension, thyroid, and other inactive diseases (Table 1). The median days to follow-up for the second visit were 18.55 (14–21), 14.3 (13–21), 15.5 (14–21), and 16 (14–20) days for the 15 μ g-BNT162b2, 30 μ g-BNT162b2, 50 μ g-mRNA-1273, and 100 μ g-mRNA-1273, respectively. The median days to follow-up for the second visit were 28.6 (27–30), 28.3 (27–35), 28.1 (28–29), and 27.9 (22–35) days for the 15 μ g-BNT162b2, 30 μ g-BNT162b2, 50 μ g-mRNA-1273, and 100 μ g-mRNA-1273, respectively.

3.2. Reactogenicity data

The most common solicited AE for all groups was injection site pain. Systemic events, including headache and myalgia. headache, joint pain, and diarrhea were more frequent in the 15 μ g- than the 30 μ g-BNT162b2 group, while joint pain and chilling were more frequent in the 100

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

μg- than the 50 μg-mRNA-1273 group (Figure 1 and Supplementary Figure S2). No severe AEs were reported. 3.3. Ig Anti-N, total Ig, and IgG anti-RBD responses Most participants were IgG anti-N seronegative (>94%) after receiving the mRNA vaccines (Supplementary Figure S3 and Table S1). There were no significant differences in the GMTs of total Ig and IgG anti-RBD between the four groups at baseline. By the second visit post-vaccination with 15 μg-BNT162b2, 30 μg-BNT162b2, 50 μg-mRNA-1273, and 100 μgmRNA-1273, total Ig anti-RBD levels were 28,413, 31,793, 41,171, and 51,979 U/mL, respectively. By the third visit, total Ig anti-RBD was slightly reduced to 21,299, 21,053, 27,282, and 33,519 U/mL, respectively (Figure 2A). Moreover, the IgG anti-RBD levels were consistent with Ig anti-RBD (Figure 2B). These results indicated that there were no significant differences in Ig and IgG anti-RBD levels between reduced and standard doses of the same vaccine. 3.4. Neutralizing antibody against the SARS-CoV-2 delta and omicron variants The sVNT against the delta and omicron variants was evaluated in a subgroup of participants. Seropositivity on the first visit was 3/40 (0.08%) and 1/40 (0.03%) to the delta and omicron variants, respectively. By the third visit, the sera of participants from all four groups achieved over 97% inhibition against the delta variant. In contrast, inhibition against the omicron variant at the third visit was 71.2%, 53.5%, 61.1%, and 76.7% in the 15 μg-BNT162b2, 30 μg-BNT162b2, 50 µg-mRNA-1273, and 100 µg-mRNA-1273 groups, respectively (Figure 3 and Supplementary Table S1). Inhibition against the omicron variant was significantly lower among participants in the 30 μ g-BNT162b2 group than participants in the other groups (p < 0.05) (Figure 3A). To assess live virus neutralization to the delta and omicron variants, FRNT₅₀ was performed. On the first visit, most participants were seronegative for FRNT₅₀ against the delta and omicron variants. By the third visit, the GMT against the delta variant in the 15 µg-BNT162b2 and 50 µg-mRNA-1273 groups increased to 1,505 and 2,088, respectively. The GMT against omicron in the 15 μg-BNT162b2 and 50 μg-mRNA-1273 groups was 343.4 and 541.2, respectively. Consistent with Ig RBD, no significant difference in FRNT₅₀ was observed in sera from the reduced and standard-dose groups of the BNT162b2 and mRNA-1273 vaccines (Figure 3B and Supplementary Table S1).

3.5. QuantiFERON assay

The T-cell response was compared between the reduced and standard doses of the mRNA vaccines in participants who previously received the two-dose CoronaVac. Results showed that the median IFN-γ CD4+ T cell and CD4+ CD8+ T cell counts were higher at the second visit than at baseline in all groups. By the third visit, IFN-γ CD4+ and CD4+ CD8+ T cell counts were slightly reduced but this was not statistically significant. Importantly, there were no differences in T cell counts between participants receiving the reduced and standard doses of each vaccine (Figure 4A-B).

4. Discussion and conclusion

This study compared the reactogenicity and immunogenicity of the reduced and standard doses of the mRNA vaccine booster in individuals who previously received a two-dose CV. A few participants had detectable IgG anti-N at baseline because they had received the two-dose CV. In agreement with Ig and IgG RBD responses, the reduced and standard-dose mRNA booster elicited high neutralizing activity against the SAR-CoV-2 delta and omicron variants. These results are consistent with a previous study of BNT162b2 following CV after three months [6]. Previous studies assessing the use of the standard mRNA vaccine dose after the CV series [1, 7] or three standard doses of BNT162b2 or mRNA-1273 [11] also demonstrated high neutralizing antibodies against the omicron variant. This aligns with another study reporting that the use of 15- μ g-BNT162b2 as a booster dose elicited neutralizing activity against the SARs-CoV-2 delta and omicron variants [7]. Nevertheless, a previous study of mRNA-1273 showed that a third standard dose (100 μ g) elicited a stronger immune response than a third reduced dose (50 μ g) [12]. However, the reduced 50 μ g-mRNA-1273 vaccine was able to elicit an immune response against the SARS-CoV-2 delta and omicron variants [12-13].

In the present study, IFN-γ release was observed by the second visit in participants who received the reduced mRNA vaccine dose. These results are consistent with previous studies of response to booster vaccination with the standard dose of mRNA vaccine after 3 [10] and 6 months [1] of CV priming. Both BNT162b2 and mRNA-1273 vaccines are able to stimulate robust antigen-specific T-cell responses after 7 days [14]. Indeed, BNT162b2 vaccination-

induces T-cell responses, including induction of IFN- γ , TNF- α , and IL-2, and protection against ancestral strains might contribute to cross-protection against the omicron variant [15].

This study had some limitations. The surrogate virus neutralization test against the delta variant reached the upper limit of >97% inhibition. However, the FRNT₅₀ result could explain why there were no significant differences in neutralizing activity against the delta and omicron variants. In addition, this study partially relied on subjects who received standard-dose immunization in another study. A more recent report of the standard-dose regimen should be used as the comparison group for the reduced-dose regimen. A follow-up study is underway to determine the durability of the booster vaccine.

In conclusion, there were no significant differences between administration of the reduced and standard doses of mRNA COVID-19 vaccine in participants who previously received inactivated CV vaccine. This study may inform decision-making regarding the use of reduced mRNA vaccine doses in healthy adults who were immunized with CV.

Acknowledgments

205

206

207

208

209

210

211

212

213

214

215

216

217

218

- We would like to thank all Center of Excellence in Clinical Virology personnel and all
- participants for helping and supporting this project. This research was financially supported by
- the Health Systems Research Institute (HSRI), National Research Council of Thailand (NRCT),
- 223 the Center of Excellence in Clinical Virology, Chulalongkorn University, and King
- 224 Chulalongkorn Memorial Hospital, and partially supported by the Second Century Fund (C2F) of
- 225 Sitthichai Kanokudom, Chulalongkorn University.
- 226 Author Contributions: Conceptualization: S.K. (Sitthichai Kanokudom), P.N., S.H. and Y.P.;
- data collection:, D.S., R.Y. and T.T. (Thaksaporn Thatsanatorn); formal analysis: S.K. (Sitthichai
- Kanokudom); Investigation: S.K. (Sitthichai Kanokudom), N.S. (Natthinee Sudhinaraset), N.W.
- and Y.P.; methodology: S.K. (Sitthichai Kanokudom), S.A., N.S. (Nungruthai Suntronwong),
- J.C., C.A., T.T. (Thanunrat Thongmee), S.K. (Sirapa Klinfueng), T.D., W.C., P.P., P.V., and
- J.M.; project administration: Y.P.; writing—original draft: S.K.(Sitthichai Kanokudom), N.W.,
- S.H. and Y.P.; writing—review and editing: S.K. (Sitthichai Kanokudom), N.W., S.H. and Y.P.
- All authors have read and agreed to the published version of the manuscript.

Funding: This research was financially supported by Health Systems Research Institute (HSRI), 234 National Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology, 235 Chulalongkorn University, and King Chulalongkorn Memorial Hospital, and partially supported 236 by the Second Century Fund (C2F) of Sitthichai Kanokudom, Chulalongkorn University. 237 **Institutional Review Board Statement**: The study protocol was approved by the Institutional 238 239 Review Board (IRB), Faculty of Medicine, Chulalongkorn University (IRB number 690/64). 240 **Informed Consent Statement**: Informed consent was obtained before participant enrollment. The study was conducted according to the Declaration of Helsinki and the Good Clinical Practice 241 Guidelines (ICH-GCP) principles. 242 Data Availability Statement: The datasets generated and analyzed during the current study are 243 available from the corresponding author on reasonable request. 244

Conflicts of Interest: The authors declare no conflict of interest.

References

- 247 [1] Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et
- al., Neutralizing activities against the omicron variant after a heterologous booster in healthy
- adults Receiving Two Doses of CoronaVac Vaccination. medRxiv 2022.
- 250 https://doi.org/10.1101/2022.01.28.22269986.
- 251 [2] Henn W, Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and
- necessary measures for global immunity. Vaccine 2020;38(34): p.5396-5397.
- 253 https://doi.org/10.1016/j.vaccine.2020.06.058.
- Wang C and Han J, Will the COVID-19 pandemic end with the delta and omicron variants?
- Environmental Chemistry Letters 2022; 1-17. https://doi.org/10.1007/s10311-021-01369-7.
- 256 [4] Kuhlmann C., Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, et al., Breakthrough
- 257 infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet
- 258 2022;399(10325): p.625-626. https://doi.org/10.1016/S0140-6736(22)00090-3.
- 259 [5] Wang SY, Juthani PV, Borges KA, Shallow MK, Gupta A, Price C, et al., Severe breakthrough
- 260 COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. Lancet Microbe 2022;3(1):
- p.e4-e5. https://doi.org/10.1016/S2666-5247(21)00306-2.
- 262 [6] Intapiboon P, Seepathomnarong P, Ongarj J, Surasombatpattana S, Uppanisakorn S,
- Mahasirimongkol S, et al., Immunogenicity and safety of an intradermal BNT162b2 mRNA
- vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population.
- Vaccines (Basel) 2021; 9(12): 1375. https://doi.org/10.3390/vaccines9121375.
- 266 [7] Angkasekwinai N, Niyomnaitham S, Sewatanon J, Phumiamorn S, Sukapirom K, Senawong S, et
- al., The immunogenicity against variants of concern and reactogenicity of four COVID-19
- booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series. medRxiv 2022.
- 269 https://doi.org/10.1101/2021.11.29.21266947.
- 270 [8] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al., Safety and efficacy
- of the BNT162b2 mRNA Covid-19 vaccine. 2020; 383(27): p. 2603-2615.
- 272 https://doi.org/10.1056/NEJMoa2034577.
- 273 [9] Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al., An mRNA
- vaccine against SARS-CoV-2 Preliminary Report. N Engl J Med 2020; 383(20): p.1920-1931.
- 275 https://doi.org/10.1056/NEJMoa2022483.
- 276 [10] Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana V, et
- al., Safety and immunogenicity of the third booster dose with inactivated, viral vector, and

278		mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines
279		(Basel) 2022; 10(1): 86. https://doi.org/10.3390/vaccines10010086.
280	[11]	Garcia-Beltran WF, Denis KJS, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al, mRNA-
281		based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron
282		variant. Cell 2022; 185(3): 457-466.e4. https://doi.org/10.1016/j.cell.2021.12.033.
283	[12]	Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, et al., SARS-CoV-2
284		Omicron variant neutralization after mRNA-1273 booster vaccination. N Engl J Med 2022.
285		https://doi.org /10.1056/NEJMc2119912.
286	[13]	Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, Nunna N, et al., Safety and immunogenicity of
287		SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med
288		2021; 27(11): p. 2025-2031. https://doi.org/10.1038/s41591-021-01527-y.
289	[14]	Li, N.L., P.T. Coates, and B.H. Rovin, COVID-19 vaccination followed by activation of
290		glomerular diseases: does association equal causation? Kidney int 2021; 100(5): p. 959-965.
291		https://doi.org/10.1016/j.kint.2021.09.002.
292	[15]	Gao Y, Cai C, Grifoni A, Müller TR, Niessl J, Olofsson A, Humbert M, et al., Ancestral SARS-
293		CoV-2-specific T cells cross-recognize the Omicron variant. Nat Med 2022
294		https://doi.org/10.1038/s41591-022-01700-x.

Figure and Table Legends

Table 1. Demographics and characteristics of the vaccinated cohorts


	BNT162b2 (15 μg)	BNT162b2 (30 μg) ^γ	mRNA-1273 (50 μg)	mRNA-1273 (100 μg) ^γ
Total number (n)	59	54	51	58
Mean age ± SD (years)	39.1±10.0	41.6±10.1	38.7±11.1	37.0±10.5
Sex				
Male (%)	28 (47.5%)	32 (59.3%)	22 (43.1%)	28 (47.8%)
Female (%)	31 (52.5%)	22 (40.7%)	29 (56.8%)	30 (52.2%)
Underlying disease (%)				
Allergy	4 (6.8%)	4 (7.4%)	5 (9.8%)	4 (6.9%)
Diabetes Mellitus	3 (5.1%)	2 (3.7%)	-	2 (3.4%)
Dyslipidemia	3 (5.1%)	4 (7.4%)	-	1 (1.7%)
Hypertension	5 (8.5%)	6 (11.1%)	3 (5.8%)	4 (6.9%)
Thyroid	1 (1.7%)	2 (3.7%)	1 (1.9%)	1 (1.7%)
Others 4	2 (3.4%)	3 (5.6%)	3 (5.8%)	2 (3.4%)
Follow-up				
Second visit (two weeks)				
Mean (range) days	18.5 (14-21)	14.3 (13-21)	15.5 (14-21)	16 (14-20)
Lost to follow-up (n)	3	1	1	0
Third visit (four weeks)				
Mean (range) days	28.6 (27-30)	28.3 (27-35)	28.1 (28-29)	27.9 (22-35)
Lost to follow-up (n)	3	0	5	2

[↓] Inactive disease—no medication involving immunosuppressant. Frevious enrolled participants of standard dose vaccination [1].

295

A

BNT162b2



B

299300

301

302

303

304

mRNA-1273




Figure 1. Reactogenicity data and risk difference analysis. The recorded incidence of AEs in participants who received the reduced booster dose with A) 15 μ g (reduced) or 30 μ g (standard) of BNT162b2 and B) 50 μ g (reduced) or 100 μ g (standard) of mRNA-1273. The risk difference with 95% CI is shown.




Figure 2. Antibody responses against SARS-CoV-2. A) Total immunoglobulin anti-RBD (U/mL) and B) IgG anti-RBD (BAU/mL). Serum was obtained from participants who received two completed doses of the inactivated vaccine, CoronaVac, followed by 15 μg (reduced) mRNA vaccine–BNT162b2, 30 μg (standard) mRNA vaccine–BNT162b2, 50 μg (reduced) mRNA-1273, or 100 μg (standard) mRNA-1273. Lines represent GMTs (95% CI); ns indicate no significant difference.




Figure 3. Neutralization assay against the SARS-CoV-2 delta (B.1.617.2) and omicron (B.1.1.529) variants. Serum samples were obtained from participants who received two completed doses of the inactivated vaccine, CoronaVac, followed by 15 μg (reduced) mRNA vaccine–BNT162b2, 30 μg (standard) mRNA vaccine–BNT162b2, 50 μg (reduced) mRNA-1273, or 100 μg (standard) mRNA-1273. A) Surrogate virus neutralization assay (sVNT); lines represent median (interquartile range). B) Focus reduction neutralization assay (FRNT₅₀); lines represent GMTs (95% CI); ns indicates no significant difference; p<0.05 (*).




Figure 4. QuantiFERON SARS-CoV-2-stimulating interferon-gamma assay. Heparinized samples were immediately incubated in a QuantiFERON (QFN) blood collection tube for 21 h. The plasma was evaluated using QFN IFN-γ ELISA. A) IFN-γ was produced by CD4-specific Ag. B) IFN-γ was produced by CD4- and CD8-specific Ag2. Lines represent medians (IQR); ns indicate no significant difference.

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

Supplementary information Supplementary Figure S1. Participant flow diagram. The cohorts were primed with the primary series of CV and received a reduced dose (experimental group) or standard dose (comparative group) of the mRNA vaccine. Supplementary Figure S2. Reactogenicity after receiving mRNA vaccine for 7 days postvaccination. The participants received two completed doses of the inactivated vaccine, CoronaVac, followed by A) 15 µg-BNT162b2, B) 30 µg-BNT162b2, C) 50 µg-mRNA-1273, or D) 100 µg-mRNA-1273. Participant percentages are shown on the Y-axis. Swelling and redness were graded by measuring the diameter area as mild (<5 cm), moderate (5 to <10 cm), and severe (>10 cm). Fever was defined as mild (38.0-38.5 °C), moderate (38.5-39.0 °C), and severe (39.0 °C). Local and systemic symptoms were graded as mild (easily tolerated with no limitation on regular activity), moderate (some limitation of daily activity), and severe (unable to perform the regular daily activity). Supplementary Figure S3. IgG anti nucleoprotein (N) of SARS-CoV-2 index (S/C). Serum samples were obtained from participants who received two completed doses of the inactivated vaccine, CoronaVac, followed by 15 µg (reduced) mRNA vaccine–BNT162b2, 30 µg (standard) mRNA vaccine–BNT162b2, 50 µg (reduced) mRNA-1273, or 100 µg (standard) mRNA-1273. Lines represent the median (interquartile range).

Supplementary Table S1. Patient serum responses during study trials.